Skip to content

Epidaurus · Treatment Guide · Mental Health & Addiction

Going abroad for —

Psychedelic Treatment Quality

Quality and safety standards of psychedelic treatment programs

The country comparison

Which countries are best for psychedelic treatment quality

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

  1. 1 Germany DE 3.5/5 Moderate Germany operates two BfArM-authorized, world-class psychedelic treatment facilities (ZI Mannheim and OVID Clinic Berlin) with expert leadership, rigorous evidence-based protocols derived from the EPIsoDE trial, and ex... Full report
    The evidence behind this score 4 cited points
    • Two BfArM-authorized facilities with expert leadership (Prof. Gründer at ZI Mannheim led the 144-patient EPIsoDE trial; Dr. Jungaberle leads only non-university German psychedelic research site)
    • Rigorous safety protocols derived from EPIsoDE Phase 2b trial using MedDRA adverse event classification, triple-blind methodology, and independent data safety monitoring; neuroimaging data collection at CIMH
    • Mandatory two-person supervision per session with at least one licensed physician; MIND Foundation APT program provides 15-month structured therapist training
    • Program capacity ~50 patients/year, restricted to German residents with treatment-resistant depression (≥2 failed antidepressants); zero international patient services or coordination infrastructure; as of late 2025 no patients treated due to administrative delays

    Read the full Germany report →

  2. 2 Israel IL 3.5/5 Moderate Israel demonstrates exceptional psychedelic research infrastructure with 7 hospital-based treatment centers, mandatory psychiatric oversight, evidence-based protocols (MAPS Phase 3 MDMA standard), and rigorous safety ... Full report
    The evidence behind this score 5 cited points
    • Seven Ministry of Health-accredited hospital-based facilities (Sheba, Hadassah, Rambam, HaEmek, Lev HaSharon, Herzog, Beer Sheva) conducting psychedelic research with mandatory psychiatrist supervision and full emergency medical infrastructure
    • Multiple professional training pathways: MAPS Israel 1-year Hakomi-based program, ACPT 5-month Psychedelic Guide Training, ACPT 10-month Psychedelic Assisted Therapy program, and Lykos/MAPS MDMA-specific clinical training based on Phase 3 protocols
    • Evidence-based MDMA protocol following MAPS Phase 3 standards: extended preparation, up to 3 eight-hour sessions over 3 months (50 hours total), with vital-sign monitoring (temperature, pulse, blood pressure), psychosis-history exclusion criteria, and pre-session ECG/blood screening
    • Rigorous regulatory oversight: all trials require Ministry of Health approval, Helsinki Committee review, pharmaceutical-grade imported substances, and mandatory outcome reporting; approximately 70% of MDMA trial participants showed PTSD symptom improvement at 2-month follow-up
    • Critical access constraint: 'Israel is a world leader in psychedelic research quality but offers near-zero dedicated access for international patients'; clinical trials restricted to Israeli residents; no commercial psychedelic retreat centers exist; no international patient coordination systems; ketamine-assisted psychotherapy at private clinics represents the only realistic pathway for medical tourists

    Read the full Israel report →

  3. 3 Spain ES 3.0/5 Moderate Spain maintains excellent clinical research infrastructure (24 psychedelic trials, ICEERS safety guidelines, international-standard hospital sites), but lacks a dedicated regulatory framework for psychedelic treatment... Full report
    The evidence behind this score 5 cited points
    • No dedicated national licensing framework for psychedelic treatment facilities exists; retreat centers operate without government inspection or minimum safety standards
    • Hospital-based research sites (Parc Sanitari Sant Joan de Déu, Hospital Sant Joan de Reus, Vall d'Hebron) operate under full AEMPS/GCP governance with international protocols and cardiologist oversight, but these are research programs with limited medical tourism access
    • Practitioner qualifications are highly variable across retreat centers with no government verification; documented safety failures exist (Harambe ibogaine incident despite claimed ECG monitoring and ACLS nurses)
    • ICEERS published internationally recognized safety guidelines for ayahuasca/ibogaine administration (December 2023) and SEMPsi is developing ethics codes and training frameworks, but these remain voluntary and non-mandatory
    • Most retreat centers lack on-site emergency medical equipment and rely on nearby hospital access; integration therapy and follow-up are limited or absent for international patients returning abroad; no coordination with home healthcare providers is systematically offered

    Read the full Spain report →

  4. 4 Brazil BR 3.0/5 Moderate Brazil operates a bifurcated psychedelic treatment landscape with world-class research institutions and 2-3 hospital-affiliated clinical facilities (Beneva ibogaine clinics, BioCase ketamine) offering qualified medica... Full report
    The evidence behind this score 5 cited points
    • Beneva operates ibogaine treatment in hospital-affiliated settings with cardiac monitoring and resuscitation infrastructure; BioCase provides ketamine clinic services; both accept medical tourists but collectively represent only 2-3 established clinical facilities
    • No national accreditation body specifically certifies psychedelic treatment centers; Alma Viva Institute's MEC authorization is the first formally recognized practitioner program, but no unified certification standard exists
    • Hospital-based ibogaine programs include comprehensive screening, structured integration, and emergency medical capabilities; ayahuasca retreat sector operates without standardized dosing protocols or mandatory contraindication screening
    • CONAD oversight of ayahuasca is described as non-binding and advisory; no government body conducts regular facility inspections; no dedicated adverse-event monitoring system exists for psychedelic-assisted therapy
    • Integration therapy available in clinical/research settings but not systematized across retreat sector; no formalized pathways coordinating international patients with home healthcare providers; language barriers impede continuity of care

    Read the full Brazil report →

  5. 5 United States US 2.5/5 Moderate The United States has emerging regulated psychedelic treatment infrastructure with Oregon's 29 licensed service centers and first professional practice guidelines, but lacks critical components needed for higher score... Full report
    The evidence behind this score 6 cited points
    • No FDA-approved psychedelic therapies; FDA rejected MDMA-assisted therapy in September 2024
    • Oregon's 29 service centers explicitly NOT classified as healthcare facilities under state law; Colorado program just beginning December 2024
    • No physician requirement for facilitators; Colorado requires only 190 hours of natural medicine training without medical degree; only 12% of US legislation specifies physician involvement
    • No centralized adverse event reporting system; most data relies on spontaneous patient/therapist reporting with identified potential for underreporting
    • Oregon requires mandatory 72-hour follow-up and integration sessions; medical consultants available but not universally mandated; no established coordination with international healthcare providers
    • 32.3% of psychedelic users traveled for treatment (42.9% to Colorado, 28.9% to Oregon, 38.5% internationally), but sessions cost $1,000-$3,000 with no insurance coverage and minimal infrastructure for international patient support

    Read the full United States report →

  6. 6 Mexico MX 2.5/5 Moderate Mexico's psychedelic treatment quality falls between poor and moderate, with extreme variability creating significant risks for medical tourists. While a small number of world-class facilities like Casa Santa Isabel i... Full report
    The evidence behind this score 6 cited points
    • Only 1-2 accredited facilities: Casa Santa Isabel is one of the only fully licensed and accredited clinics by local, state, and federal regulatory boards in Mexico
    • No mandatory training requirements: No government-mandated training or certification requirements for practitioners; no formal requirements for training or credentials for psychedelic facilitators
    • Regulatory vacuum: COFEPRIS's role in psychedelic treatment oversight remains minimal, and no formal regulatory framework has been established despite COFEPRIS being tasked with drug oversight
    • Integration therapy gap: Integration therapy and follow-up care represent significant gaps in many Mexican psychedelic treatment programs; many facilities lack structured integration programs entirely
    • Extreme quality variability: Some centers follow strict medical protocols with 24/7 supervision and continuous cardiac monitoring, while others lack thorough medical screening, trained staff, and on-site medical professionals
    • Limited medical tourism services: Minimal evidence of systematic coordination between Mexican treatment facilities and patients' home healthcare providers

    Read the full Mexico report →

  7. 7 Colombia CO 2.0/5 Poor Colombia's psychedelic treatment sector lacks formal regulatory oversight, accreditation, or standardized clinical protocols. Approximately 21 facilities operate without government licensing or inspection, and medical... Full report
    The evidence behind this score 5 cited points
    • No formal accreditation system or sector-specific licensing: approximately 21 retreat facilities operate without government oversight, inspection, or certification standards
    • Inconsistent practitioner qualifications and training: traditional Taitas have decades of apprenticeship but no biomedical credentials; medical supervision is voluntary at some centers only, with no specialized psychedelic medicine training requirements
    • No standardized clinical protocols or mandatory safety monitoring: facility practices vary widely; adverse event reporting system does not exist; government inspections do not occur
    • Weak regulatory framework: INVIMA has no approved treatment pathway for classic psychedelics; FNE authorized psilocybin research (not treatment) for one company; Constitutional Court protects indigenous ayahuasca practice but does not mandate clinical standards
    • Emerging voluntary best practices: some centers offer pre-screening for contraindications, cap group sizes at 8–15 participants, and provide integration therapy with ongoing follow-up, demonstrating movement toward quality standards despite lack of mandate

    Read the full Colombia report →

  8. 8 Malaysia MY 1.0/5 Poor Malaysia prohibits all psychedelic substances under the Dangerous Drugs Act 1952 with severe criminal penalties including death for trafficking, making therapeutic psychedelic treatment entirely unavailable. Zero lice... Full report
    The evidence behind this score 8 cited points
    • The Dangerous Drugs Act 1952 absolutely prohibits manufacture, sale, supply, and use of psilocybin, DMT, MDMA, LSD, and ibogaine; no therapeutic-use exemptions exist
    • Zero licensed or accredited psychedelic treatment facilities operate in Malaysia
    • The only identified operator (The Violet Flame KL) discloses no medical licensing, accreditation, emergency protocols, or practitioner medical qualifications
    • No standardized clinical protocols, dosing standards, purity testing, or patient screening requirements exist for psychedelic treatment
    • No medical monitoring, on-site emergency capabilities, or adverse event reporting systems are in place; psychedelic substance administration occurs entirely outside medical oversight
    • No integration therapy ecosystem exists; no Malaysian practitioners are trained in psychedelic-assisted therapy
    • Malaysia's regulatory framework treats psychedelic substances through criminal law rather than health regulation, with the death penalty available for trafficking following abolition of mandatory capital punishment in 2023
    • Medical tourists face severe legal jeopardy (imprisonment, corporal punishment), zero quality assurance, no safety infrastructure, and no credentialed support if harmed

    Read the full Malaysia report →

  9. 9 Poland PL 1.0/5 Poor Poland has no regulated psychedelic treatment facilities accepting medical tourists. All classical psychedelics are Group I-P controlled substances under the 2005 Act on Counteracting Drug Addiction with criminal pena... Full report
    The evidence behind this score 5 cited points
    • No licensed or internationally accredited psychedelic treatment facilities exist in Poland—only research sites
    • All classical psychedelics (psilocybin, MDMA, LSD, ibogaine, DMT) are Group I-P controlled substances with penalties up to 3 years imprisonment for possession
    • No therapeutic exemption process exists comparable to Switzerland's named patient programs or Germany's 2024 reforms
    • Psilocybin trial led by Medical University of Warsaw is in approvals phase, awaiting EMA and Chief Sanitary Inspectorate clearance; not yet recruiting
    • Polish Society for Psychedelic Integration explicitly advises that 'the only legal form of psychotherapy using psychedelic substances [in Poland] is therapy using ketamine' and recommends seeking treatment elsewhere

    Read the full Poland report →

  10. 10 Singapore SG 1.0/5 Poor Singapore has zero regulated psychedelic treatment facilities, no practitioner training infrastructure, and no standardized clinical protocols for psychedelic-assisted therapy. The country operates under a prohibition... Full report
    The evidence behind this score 5 cited points
    • No accredited or licensed psychedelic treatment facilities exist in Singapore; all classic psychedelics are Class A controlled drugs under the Misuse of Drugs Act 1973
    • No Singapore Medical Council framework, training curriculum, or certification pathway for psychedelic medicine exists; the practice itself is criminally prohibited
    • Possession of MDMA or psilocybin mushrooms carries up to 10 years imprisonment and S$20,000 fine; trafficking carries mandatory life imprisonment or death penalty
    • Singapore's 2023 National Mental Health and Well-Being Strategy contains no mention of psychedelic-assisted therapy; the 2023 amendments to the Misuse of Drugs Act strengthened rather than liberalized enforcement
    • Drug traffickers were executed in April 2026, November 2025, and September 2025, demonstrating active enforcement of death penalty provisions

    Read the full Singapore report →

  11. 11 Thailand TH 1.0/5 Poor Thailand has no legally licensed psychedelic treatment facilities despite a 2024 regulatory change permitting research use only. All facilities are unregulated retreats lacking medical supervision, standardized protoc... Full report
    The evidence behind this score 7 cited points
    • No regulated psychedelic treatment facilities currently operating for medical tourists despite Thailand's 2024 Ministerial Notification permitting research use
    • British tourist died in 2024 from suspected magic mushroom consumption at Mae Rim District resort in Chiang Mai, demonstrating serious safety risks
    • Magic mushrooms classified as Category 5 narcotic with criminal penalties up to 1 year imprisonment for users or 5 years for possession/distribution
    • Unregulated retreat centers on Ko Samui and Koh Pha Ngan operate without licensing, medical screening, or proper integration support
    • Professional psychedelic therapy organizations legally registered in Thailand explicitly do not conduct treatments in the country due to inability to access relevant legislation and legal pathways
    • No medical supervision standards, training requirements, or standardized clinical protocols exist for psychedelic treatment in Thailand
    • No regulatory oversight system extends to psychedelic treatment facilities, only traditional rehab facilities

    Read the full Thailand report →

  12. 12 Turkey TR 1.0/5 Poor Turkey offers no legal psychedelic-assisted therapy, regulated treatment facilities, or licensed practitioners for psychedelic medicine. All psychedelics remain completely illegal under Law No. 2313, with severe crimi... Full report
    The evidence behind this score 5 cited points
    • All psychedelics remain illegal in Turkey under Law No. 2313 with use, prescription and monitoring subject to a special and controlled system overseen by the Ministry of Health
    • No internationally accredited psychedelic treatment facilities, research programs accepting medical tourists, or licensed psychedelic medicine practitioners exist in the country
    • Turkey operates 143 AMATEM and ÇEMATEM addiction treatment centers but these centers focus exclusively on conventional addiction treatment methods without any psychedelic medicine components
    • No standardized psychedelic treatment protocols exist in Turkey because psychedelic-assisted therapy is illegal
    • Penalties for production, import, export and trafficking rank among the heaviest sanctions in Turkish criminal law, often comparable to those imposed for organized crime and terrorism-related offences

    Read the full Turkey report →

  13. 13 Jordan JO 1.0/5 Poor Jordan offers no regulated psychedelic treatment facilities or practitioners qualified in psychedelic medicine. Psychedelic substances are criminalized under the Narcotic Drugs and Psychotropic Substances Law with pen... Full report
    The evidence behind this score 4 cited points
    • No licensed psychedelic treatment facilities exist in Jordan; the country's medical tourism infrastructure specializes exclusively in conventional care (cardiac surgery, oncology, orthopedics, fertility) [Jordan Medical Tourism - Medical Tourism - 2024]
    • Jordan has approximately 87 psychiatrists nationally, trained only in conventional pharmacotherapy with no qualifications or training pathways in psychedelic medicine [Mental Health in Jordan - The Borgen Project - 2024]
    • Possession of psychedelic substances carries criminal penalties of 3 months to 2 years imprisonment under the 2021 Narcotic Drugs and Psychotropic Substances Law, with trafficking penalties up to 25 years and no medical necessity defense [Amendments to Narcotic Drugs and Psychotropic Substances Law passed - Jordan Times - 2021]
    • No safety monitoring, emergency preparedness, session management protocols, or integration therapy programs exist for psychedelic-assisted therapy; the legal framework addresses only conventional drug addiction treatment [National Mental Health and Substance Use Action Plan 2022-2026 - Ministry of Health Jordan - 2022]

    Read the full Jordan report →

  14. 14 United Kingdom GB 1.0/5 Poor The United Kingdom has no regulated psychedelic treatment facilities accepting medical tourists, despite hosting world-class research infrastructure. All therapeutic access is confined to MHRA/HRA-approved clinical tr... Full report
    The evidence behind this score 5 cited points
    • No regulated commercial psychedelic therapy accessible to medical tourists; all facilities operate as research sites only
    • Royal College of Psychiatrists September 2025 position statement: evidence insufficient for routine clinical use outside licensed trial settings
    • Clinical trials not structured for medical tourism; require domestic NHS eligibility criteria and multi-week commitments
    • World-class research infrastructure exists (Clerkenwell Health, Maudsley Centre, Cambridge, Imperial College) but entirely confined to clinical trials
    • Underground market is active but unsafe; 2024 BMC Psychiatry case report documents severe adverse effects from unregulated therapy

    Read the full United Kingdom report →

  15. 15 Hungary HU 1.0/5 Poor Hungary has no licensed psychedelic treatment facilities accepting medical tourists and a comprehensive legal prohibition of all classical psychedelics criminalized under Penal Code with up to two years imprisonment f... Full report
    The evidence behind this score 5 cited points
    • No licensed or accredited psychedelic treatment facilities exist in Hungary; all classical psychedelics (psilocybin, MDMA, LSD, ayahuasca) are criminalized with criminal penalties of 2-20 years imprisonment
    • April 2025 Constitutional Amendment 15 explicitly prohibited production, use, distribution, and promotion of narcotics at constitutional level, cementing one of Europe's most restrictive frameworks
    • One MAPS-certified MDMA-Assisted Psychotherapy therapist in Budapest (PsyAid Budapest) has stated that Hungarian regulations prohibit administering MDMA
    • Harm reduction infrastructure dismantled: 90% funding cuts in 2025, Budapest's largest harm reduction centers closed, eliminating safety nets for adverse reactions
    • No national safety protocols, standardized clinical protocols, or integration therapy programs for psychedelic treatment; psychiatric system reaches only ~10% of serious mental health needs

    Read the full Hungary report →

  16. 16 India IN 1.0/5 Poor India prohibits all classic psychedelic-assisted therapies under the NDPS Act of 1985 and offers no regulated treatment facilities, accreditation standards, or medical supervision protocols for medical tourists. All p... Full report
    The evidence behind this score 5 cited points
    • The NDPS Act of 1985 classifies psilocybin, DMT (ayahuasca component), LSD, and MDMA as prohibited substances with possession, production, or consumption resulting in severe legal repercussions including imprisonment.
    • No accredited or licensed facilities offer regulated psychedelic-assisted therapy; any ayahuasca retreat in India would be underground and unregulated with no standardized safety protocols.
    • No practitioner certification pathway exists for psychedelic medicine; the use of psychedelic therapy would require immense training for mental health professionals currently unavailable in India.
    • Medical tourists face criminal prosecution risks, with the NDPS Act operating on reverse burden of proof where the accused must prove lawful possession.
    • Absence of integration therapy, follow-up care systems, or medical tourism infrastructure specifically for psychedelic treatments.

    Read the full India report →

  17. 17 United Arab Emirates AE 1.0/5 Poor The UAE has zero regulated psychedelic treatment facilities, criminalizes all classical psychedelic substances under federal law, lacks any clinical protocols or practitioner credentialing framework, and has recently ... Full report
    The evidence behind this score 5 cited points
    • Zero licensed or accredited psychedelic treatment facilities exist in the UAE; existing psychiatric hospitals (Al Amal, NRC) do not offer psychedelic programs
    • All classical psychedelic substances (DMT, tryptamine including psilocybin) are Schedule I/V controlled substances under Federal Decree-Law No. 30 of 2021 and Federal Decree Law No. 73 of December 2025
    • No national credentialing framework, certification pathways, or training standards for psychedelic medicine practitioners; unauthorized dispensing carries minimum 5-year prison sentence
    • No standardized clinical protocols, safety monitoring standards, or regulatory oversight framework for psychedelic treatment in UAE law or regulatory agency guidance
    • Federal Decree Law No. 73 (December 2025) made deportation mandatory for foreign nationals convicted of drug offenses; prosecution applies to residual metabolites regardless of where substance was legally consumed

    Read the full United Arab Emirates report →

  18. 18 Japan JP 1.0/5 Poor Japan operates under a near-total prohibition of classical psychedelics with severe criminal penalties, and no regulated psychedelic treatment facilities, practitioner training programs, or clinical protocols exist. A... Full report
    The evidence behind this score 6 cited points
    • All classical psychedelics are criminalized under the Narcotics and Psychotropics Control Law with penalties up to 7 years imprisonment
    • Zero licensed or accredited psychedelic treatment facilities exist in Japan as of 2026
    • No professional training programs, certification pathways, or specialization routes exist for psychedelic medicine practitioners in Japan
    • No standardized treatment protocols, safety monitoring standards, or integration therapy services have been established
    • Foreign nationals convicted of drug offenses face mandatory deportation and a five-year re-entry ban
    • Keio University's psilocybin research is in early feasibility stages and does not accept medical tourists

    Read the full Japan report →

  19. 19 South Korea KR 1.0/5 Poor South Korea receives a Score 1 because psychedelic-assisted therapy is entirely illegal with zero licensed treatment facilities, no authorized practitioners, and severe criminal penalties (5 years to life imprisonment... Full report
    The evidence behind this score 4 cited points
    • Zero licensed psychedelic treatment facilities exist in South Korea; all such treatment is illegal under the Narcotics Control Act
    • No medical practitioners are legally authorized to administer psychedelic-assisted therapy, and psilocybin and other psychedelics are classified as controlled psychotropic substances
    • Drug-related crimes carry minimum sentences of 5 years up to life imprisonment, and foreign nationals can face deportation and permanent bans from re-entry
    • There are no safety monitoring protocols, emergency preparedness procedures, or standardized treatment protocols because psychedelic-assisted therapy is entirely prohibited

    Read the full South Korea report →

Reading the field

What separates a good programme from a dangerous one

Every country above is graded against this published scale — the same 1–5 rubric for psychedelic treatment quality, top to bottom. How we score →

  1. 5/5 Excellent

    - 5+ internationally accredited psychedelic treatment facilities with comprehensive medical supervision - Mandatory physician specialization in psychedelic medicine with 40+ hours annual training requirements - Standardized clinical protocols with evidence-based therapeutic frameworks and rigorous safety monitoring - 24/7 on-site emergency medical capabilities with documented response protocols - Comprehensive integration therapy programs with 6+ month follow-up protocols - Robust regulatory oversight with quarterly inspections and public outcome reporting - Medical tourism patient-specific services including coordination with home providers

  2. 4/5 Good

    - 3-4 accredited treatment facilities with qualified medical supervision - Licensed physicians required with psychedelic medicine training (20+ hours annually) - Established clinical protocols with safety monitoring and therapeutic support - On-site medical emergency capabilities during treatment sessions - Integration therapy available with 3+ month follow-up - Regular regulatory inspections and compliance monitoring - Some coordination services for international patients

  3. 3/5 Moderate

    - 1-2 licensed treatment facilities with basic medical oversight - Medical supervision required but limited specialized psychedelic training (10+ hours) - Basic safety protocols with minimal standardization across facilities - Emergency medical access available (on-call or nearby hospital) - Limited integration therapy and follow-up services - Basic regulatory compliance with annual inspections - Minimal specific services for medical tourism patients

  4. 2/5 Poor

    - Limited licensed facilities with questionable medical supervision standards - Inconsistent practitioner qualifications and minimal specialized training - Basic safety measures with significant protocol variations - Limited emergency medical capabilities - Minimal or no integration therapy services - Weak regulatory oversight with infrequent inspections - No specific accommodations for international patients

  5. 1/5 Very Poor / Unavailable

    - No regulated psychedelic treatment facilities accepting medical tourists - Unqualified practitioners or no medical supervision requirements - Inadequate safety protocols and emergency preparedness - No standardized clinical protocols or quality assurance - No integration or follow-up care systems - Minimal or no regulatory oversight - Unsafe or illegal treatment options only

The reports

The full country reports under this lens

Each destination we have assessed has a full, cited report — the detailed analysis behind its score. The verdict is free; the report is the depth.

Clinics & providers

The clinics our research names

Named hospitals, clinics and centres cited across these findings — each carrying the specialties our reports record. Follow one to the reports behind it.

References

The sources behind these assessments

The distinct sources cited across these published reports — every finding carries its own citations; this is the union, each linking back to the reports that lean on it.

  1. Untitled source 10mag.com/9-english-speaking-psychologists-in-korea Cited in Psychedelic Treatment Quality in South Korea
  2. Untitled source 2009-2017.state.gov/j/inl/rls/nrcrpt/2016/vol1/253316.htm Cited in Psychedelic Treatment Quality in Turkey
  3. Untitled source archivesbiologicalpsychiatry.org/psychedelic-therapy-cant-stop-the-wave-lets-learn-to-surf Cited in Psychedelic Treatment Quality in India
  4. Untitled source asianews.network/thailand-allows-use-of-opium-magic-mushrooms-for-medical-purposes-research Cited in Psychedelic Treatment Quality in Thailand
  5. Untitled source ayahuascaincolombia.com/2024/07/30/setting-boundaries-ensuring-a-safe-ayahuasca-experience Cited in Psychedelic Treatment Quality in Colombia
  6. Untitled source basseibogaine.com/safe-ibogaine-retreat-mexico Cited in Psychedelic Treatment Quality in Mexico
  7. Untitled source blog.southofseoul.net/understanding-types-of-mental-health-services-in-korea Cited in Psychedelic Treatment Quality in South Korea
  8. Untitled source blossomanalysis.com/countries/mexico Cited in Psychedelic Treatment Quality in Mexico
  9. Untitled source bookretreats.com/s/other-retreats/psilocybin-retreats/thailand Cited in Psychedelic Treatment Quality in Thailand
  10. Untitled source cannadelics.com/2022/09/12/thailand-getting-in-on-psilocybin-mushrooms-therapy Cited in Psychedelic Treatment Quality in Thailand
  11. Untitled source chacruna.net/plant-medicine-in-mexico-from-traditional-use-to-psychedelic-therapy Cited in Psychedelic Treatment Quality in Mexico
  12. Untitled source compassionretreats.com/blog/6-mexico-today-tradition-tourism-tribulations Cited in Psychedelic Treatment Quality in Mexico
  13. Untitled source drprakharjain.com/ketamine-therapy-in-india Cited in Psychedelic Treatment Quality in India
  14. Untitled source elaw.klri.re.kr/eng_mobile/viewer.do?hseq=50166&type=sogan&key=31 Cited in Psychedelic Treatment Quality in South Korea
  15. Untitled source en.seoulcentralmhc.com Cited in Psychedelic Treatment Quality in South Korea
  16. Untitled source en.wikipedia.org/wiki/Cannabis_in_South_Korea Cited in Psychedelic Treatment Quality in South Korea
  17. Untitled source en.wikipedia.org/wiki/Cannabis_in_Thailand Cited in Psychedelic Treatment Quality in Thailand
  18. Untitled source en.wikipedia.org/wiki/Narcotic_Drugs_and_Psychotropic_Substances_Act,_1985 Cited in Psychedelic Treatment Quality in India
  19. Untitled source en.wikipedia.org/wiki/Turkish_Medicines_and_Medical_Devices_Agency Cited in Psychedelic Treatment Quality in Turkey
  20. Untitled source evolvingtemple.org/thailand-embraces-opium-and-magic-mushrooms Cited in Psychedelic Treatment Quality in Thailand
  21. Untitled source filtermag.org/europeaccess-psychedelic-therapy-breakthrough Cited in Psychedelic Treatment Quality in Hungary
  22. Untitled source hackskorea.com/mental-health-korea-foreigners Cited in Psychedelic Treatment Quality in South Korea
  23. Untitled source healingmaps.com/region/mexico Cited in Psychedelic Treatment Quality in Mexico
  24. Untitled source health.clevelandclinic.org/ayahuasca Cited in Psychedelic Treatment Quality in India

Explore the source archive →

In plain language

Start exploring the knowledge base

The field's shorthand our reports use, sized by how often it comes up. Follow any term to its full entry and the reports that use it.

For readers weighing this decision

Ways to read the evidence

The verdict is always free. A membership opens the full analysis and every cited source — this specialty, the whole library, or everything for good.

  • One specialty · annual

    Mental Health & Addiction

    $49.00 / year

    $49.00/year

    Every report in this specialty — full analysis and every cited source — as each is published.

    Take this specialty

  • Full library · annual

    The whole library

    $199.00 / year

    $199.00/year

    The complete evidence behind every finding in every specialty, while your decision is live.

    Take the full library
  • Most readers

    Lifetime · one payment

    Everything, for good

    $499.00 once

    $499.00 (one-time)

    Every finding we publish today and hereafter — no renewal, no expiry. The tier we point most readers to.

    Take lifetime access

Prefer to pay per report? A single report is $29.00, yours to keep — browse the reports. The verdict is always free.

Where to go from here · Psychedelic Treatment Quality

no scope is a dead end — step up to the specialty, drill into a factor, or pivot across to a country or a comparison